This special report focuses on the research and people of the San Diego tech and biotech industries, as well as the local lab market and intellectual property issues.

  • Despite collaborative research environment, local biotechs face regulatory issues, lack of venture capital

    A highly collaborative research environment between life sciences companies, universities and trade organizations has made San Diego an attractive location for biotechnology startups and big manufacturers.

  • SKCC scientist receives grant for promising lung cancer therapy

    Research advancements in cancer therapy are beautiful music to the ears of lung cancer patients everywhere. One-time La Jolla Symphony violinist Ruth Gjerset is striking an important chord, recently receiving an award of $100,000 from the Joan Scarangello Foundation to Conquer Lung Cancer. Gjerset's work using gene therapy as a way of suppressing the growth of tumors is currently under way at the Sidney Kimmel Cancer Center.

  • Leader of life sciences group unfazed by limited land supply for biotechs

    According to the San Diego Regional Chamber of Commerce and San Diego Association of Governments, biotechnology in San Diego is roughly a $9 billion industry employing 40,000 people, and Doug Lozier is in the middle of the action.

  • Biotechs employ creative financing alternatives in changing market

    Biotechnology companies have looked to ever more creative financing alternatives as changing market conditions have resulted in increasingly limited access to funding from traditional sources, such as venture capital financing and initial public offerings. Due to the widespread failure of many startups, including the fallout from the genomics bubble burst in 2000, and the introduction of the costly Sarbanes-Oxley requirements, early-stage biotechs are facing greater challenges in securing financing on reasonable terms.

  • San Diego lab market dynamic, not stagnant

    Some complain San Diego's lab market has been slow or stagnant for several years; others have even gone as far as to call the lab market sick. However, there is a relevant amount of activity that indicates the market's outlook is not as grim as some believe.

  • Monsanto and BASF announce partnership for biotech crops

    Monsanto (NYSE: MON) and BASF (NYSE: BF) announced a partnership Wednesday to develop new genetically engineered crops.

  • Judge issues permanent injunction against Vonage

    ALEXANDRIA, Va. -- A federal judge on Friday issued a permanent injunction against Internet phone company Vonage (NYSE: VG) for use of Verizon Communications Inc.'s patents.

  • The Burnham Life Sciences Group: Unparalled biotech transaction experience

    The Burnham Life Sciences Group is San Diego County's oldest and most experienced real estate team specializing exclusively in meeting the unique needs of the biotechnology industry. Beginning with Hybritech's first facility in 1979, the Burnham Life Sciences Group has continued to be San Diego's leading provider of biomedical real estate services, routinely negotiating more than 65 percent of life sciences-related leases in the region.

  • A who's who of firsts

    The law firm of Fish & Richardson can cite many firsts as part of its distinguished 130 years of serving great innovators, helping to protect countless ideas, nurturing discoveries and bringing new concepts to market.

  • Music publishers suit claims copyright abuse by XM Satellite Radio

    NEW YORK -- A group representing music publishers is suing XM Satellite Radio (Nasdaq: XMSR), saying that XM violates copyright laws by giving users the ability to store and replay songs on certain devices.

  • Oracle sues German rival for alleged theft of product information

    SAN FRANCISCO -- Oracle Corp. (Nasdaq: ORCL) accused its German rival SAP AG (NYSE: SAP) of hacking into its computers to heist secret product information in a lawsuit that highlights the escalating tensions between two of the world's largest business software makers.

  • Burnham Real Estate's lab market report: Negotiating a market in transition

    In its recently released 2006 Annual Lab Report, the Burnham Life Sciences Group said San Diego County continues to experience heightened demand for laboratory space, reflected by steadily declining vacancy and a market that will be increasingly challenged to meet the fast changing needs of the biotech industry.

  • Outsourcing patent work

    Fueled by many factors, legal costs for patent work have seen astronomical increases. At the same time, many companies are under pressure to reduce their patent costs. Not surprisingly, this has led many companies to seek lower-cost providers of patent work.

  • Emerging drugs show promise against HIV

    After a dearth of new drugs for people infected with HIV, this year promises a bumper crop of medicines that may help combat rising resistance to older therapies.

  • Biotech goes to the garden

    Petunias that survive frost. Impatiens that shrug off drought. Disease-free geraniums. They sound like dream plants for gardeners.

  • Tech companies bleeding red ink pursue IPO gold

    Technology companies that bleed red ink are once again lining up to go public -- and once again finding plenty of takers.

  • From Wall Street, a warning about cancer-drug prices

    Two years ago, Steven Harr urged Genentech Inc. (NYSE: DNA) to lower the price of a key drug that was helping buoy its stock price. He was an unlikely messenger because of his job: a Wall Street research analyst whose investing clients crave profits.

  • Scientist sees rich promise in tiny organisms

    Marine microbes are among the most abundant life form on the planet and among the most mysterious. Now, results from the first phase of a global expedition are expected to provide a glimpse into this long-hidden world while potentially leading to new drugs and even fighting climate change.

  • Stemagen, UPenn partner to advance therapeutic use of stem cells

    Stemagen has acquired the exclusive rights to a patent for a groundbreaking technique that allows the development of embryonic stem cells appearing to have a markedly enhanced potential for therapeutic use - uniparental embryonic stem cells. Because these extraordinary stem cells are created without fertilization, they may represent an acceptable alternative for those who oppose the traditional method that requires the use of embryos that are potentially capable of reproduction.

  • Patent drafting considerations for high-tech inventions

    Patent drafting strategies in complex technical areas can be "field-specific." Despite the efforts of the U.S. Patent and Trademark Office to apply generic standards, claim language that is acceptable in one field might inadvertently lead to difficulties in establishing patentability in another. Since high-tech subject matter is complex and often crosses over into multiple technical areas, claiming strategies that are likely to enhance favorable prosecution need to be carefully developed. This article presents some of the important points to consider when writing a high-technology patent application, with particular emphasis on claim drafting.

  • Clean technology cultivates new perspectives on energy

    It's clean, green and holds the seeds to better efficiency in the ways businesses utilize energy.

  • Legal, tech experts: Use caution when putting IP online

    Despite the constantly increasing capabilities and reach of the Internet, the same legal protections for intellectual property apply, according to San Diego attorney Ross Epstein.

  • Artes Medical reports $26.3 million net loss

    Artes Medical Inc., a San Diego-based medical technology company, reported a net loss of $26.3 million for the fiscal year ended Dec. 31, 2006, taking an $8.2 million hit in the fourth quarter alone.

  • Broadcom urges panel to block imports with Qualcomm chips

    The chief executive of Broadcom Corp. (Nasdaq: BDCM) urged a government panel Wednesday to bar imports of cell phones that include chips made by (Nasdaq: QCOM) Qualcomm Inc. that infringe on its patents.

  • Qualcomm, Nokia exchange allegations

    Qualcomm Inc. Tuesday denied allegations made in complaints Nokia reportedly filed against the San Diego-based company in Germany and the Netherlands.

  • Connect launches new index to track local technology startups

    In an effort to bolster San Diego’s position as an important center for technology and life sciences, local business organization Connect has unveiled a new quarterly index that will track and monitor the creation of new technology companies within the county.

  • Acadia sees positive results from schizophrenia treatment trial

    Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced positive top-line results Monday from its Phase II schizophrenia co-therapy trial with ACP-103, ACADIA’s proprietary and selective 5-HT2A inverse agonist.

  • 3 research institutes net $16 million in stem cell funding

    The California Institute for Regenerative Medicine announced a second round of grant funding for stem cell research Friday, awarding more than $16 million to research institutions in the San Diego area.

  • Carlsbad biotech cites time difference between offices as reason for relocation

    Biotech drug developer Micromet entered a lease agreement Friday intended to relocate its Carlsbad headquarters to Maryland, a company executive said.

  • Microsoft CEO unveils management program during San Diego visit

    Microsoft Corp. CEO Steve Ballmer gave thousands of customers a sneak peak Wednesday afternoon at a highly anticipated product he said will help fuel business productivity.

  • Designed with golf in mind, ProSked spreads to other business uses

    Ideas can about from all different places. One of Jerry Dressel’s biggest ideas came out of a frustrating experience with golf.

Who's Who in Tech and Biotech


National News